Although the second messenger cyclic AMP (cAMP) is physiologically beneficial in the heart, it largely contributes to cardiac disease progression when dysregulated. Current evidence suggests that cAMP is produced within mitochondria. However, mitochondrial cAMP signaling and its involvement in cardiac pathophysiology are far from being understood.
To investigate the role of mitochondrial exchange protein directly activated by cAMP 1 (MitEpac1) in ischemia/reperfusion (I/R) injury.
We show that Epac1 genetic ablation (Epac1(-/-)) protects against experimental myocardial I/R injury with reduced infarct size and cardiomyocyte apoptosis. As observed in vivo, Epac1 inhibition prevents hypoxia/reoxygenation (HX+R)- induced adult cardiomyocyte apoptosis. Interestingly, a deleted form of Epac1 in its mitochondrial-targeting sequence protects against HX+R- induced cell death. Mechanistically, Epac1 favors Ca(2+) exchange between the endoplasmic reticulum and the mitochondrion, by increasing interaction with a macromolecular complex composed of the voltage-dependent anion channel 1 (VDAC1), the chaperone glucose-regulated protein 75 (GRP75), and the inositol-1,4,5-triphosphate receptor 1 (IP3R1) leading to mitochondrial Ca(2+) overload and opening of the mitochondrial permeability transition pore (MPTP). In addition, our findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 (IDH2) via the mitochondrial recruitment of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII), which decreases nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) synthesis, thereby reducing the antioxidant capabilities of the cardiomyocyte.
Our results reveal the existence, within mitochondria, of different cAMP-Epac1 microdomains that control myocardial cell death. In addition, our findings suggest Epac1 as a promising target for the treatment of ischemia- induced myocardial damage.